Leptanal (Fentanyl)
Potent synthetic opioid analgesic for anesthesia and severe pain management
Leptanal is a brand name for fentanyl citrate, a potent synthetic opioid analgesic approximately 80–100 times more potent than morphine. It is used primarily in hospital settings as part of general anesthesia, for perioperative pain management, and in intensive care for severe acute pain. Because of its rapid onset and short duration of action, fentanyl is one of the most widely used opioids in modern anesthesia practice worldwide. Leptanal is administered only by trained healthcare professionals in monitored clinical environments.
Quick Facts: Leptanal (Fentanyl)
Key Takeaways
- Leptanal (fentanyl) is approximately 80–100 times more potent than morphine and is used primarily during surgical anesthesia and in intensive care settings.
- It must only be administered by trained healthcare professionals with immediate access to resuscitation equipment, including airway management devices and naloxone.
- The most serious risk is respiratory depression, which can be life-threatening and requires continuous monitoring of respiratory function.
- Fentanyl has significant drug interactions, particularly with benzodiazepines, MAO inhibitors, and CYP3A4 inhibitors, which can increase the risk of severe adverse effects.
- As a Schedule II controlled substance, fentanyl carries a high potential for abuse and physical dependence; strict protocols govern its storage, prescribing, and administration.
What Is Leptanal and What Is It Used For?
Leptanal contains the active ingredient fentanyl citrate, a fully synthetic opioid agonist that was first synthesized in 1960 by Paul Janssen. Since its introduction into clinical practice in 1968, fentanyl has become one of the most commonly used opioids in anesthesia worldwide. It belongs to the phenylpiperidine class of synthetic opioids and is listed on the WHO Model List of Essential Medicines, underscoring its critical importance in global healthcare.
Fentanyl exerts its pharmacological effects primarily through binding to mu-opioid receptors (MOR) in the central nervous system. This binding triggers a cascade of intracellular signaling that results in potent analgesia, sedation, and a reduction in the sympathetic stress response to surgical stimulation. Its high lipophilicity allows it to cross the blood-brain barrier rapidly, which accounts for its characteristically fast onset of action—typically 1 to 2 minutes when administered intravenously.
In clinical practice, Leptanal is used in several distinct scenarios. During general anesthesia, it is used as the primary analgesic component, often combined with a hypnotic agent (such as propofol) and a neuromuscular blocking agent. In balanced anesthesia, lower doses of fentanyl supplement inhaled anesthetic agents to reduce their required concentration and associated cardiovascular side effects. In cardiac surgery, high-dose fentanyl techniques (50–100 micrograms/kg) provide hemodynamic stability during cardiopulmonary bypass procedures.
Beyond the operating room, fentanyl is used in intensive care units for sedation and analgesia in mechanically ventilated patients, in procedural sedation for painful diagnostic or therapeutic procedures, and as a supplement to regional anesthesia when added to epidural or spinal local anesthetic solutions. The injectable formulation that Leptanal represents is specifically designed for these acute, monitored clinical contexts and is distinct from transdermal patches or transmucosal formulations used for chronic pain.
Pharmacokinetics
Understanding how fentanyl moves through the body is essential for safe clinical use. After intravenous administration, fentanyl is rapidly distributed to highly perfused tissues including the brain, heart, and lungs. It has a volume of distribution of approximately 4 L/kg, reflecting its extensive tissue distribution. The drug is approximately 80–85% bound to plasma proteins, primarily alpha-1-acid glycoprotein and albumin.
Fentanyl is metabolized primarily in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system through N-dealkylation to norfentanyl, which is pharmacologically inactive. Approximately 75% of a dose is excreted in the urine (primarily as metabolites, with less than 10% as unchanged drug), and about 9% is excreted in feces. The elimination half-life is 3–4 hours after a single intravenous dose, but this can increase significantly with repeated dosing or prolonged infusions due to redistribution from peripheral compartments (the "context-sensitive half-time").
What Should You Know Before Receiving Leptanal?
While Leptanal is administered by healthcare professionals who will perform a thorough pre-anesthetic assessment, it is important for patients to understand the safety considerations involved. The prescribing physician must evaluate each patient's individual risk profile, including comorbidities, concurrent medications, and personal history, before deciding on the appropriate use and dosing of fentanyl.
Contraindications
Leptanal must not be administered in the following circumstances:
- Known hypersensitivity to fentanyl, other opioid agonists, or any of the excipients in the formulation.
- Severe respiratory depression without mechanical ventilation support, as fentanyl will worsen respiratory compromise.
- Concurrent or recent use of monoamine oxidase inhibitors (MAOIs)—fentanyl must not be given within 14 days of MAOI use due to the risk of serotonin syndrome and potentiated opioid effects, including severe respiratory depression and cardiovascular instability.
- Obstructive airway disease in patients not being mechanically ventilated, where respiratory depression could be fatal.
- Known or suspected paralytic ileus, as opioids reduce gastrointestinal motility.
Warnings and Precautions
Healthcare providers must exercise particular caution when using Leptanal in patients with the following conditions:
- Chronic obstructive pulmonary disease (COPD) or other chronic respiratory conditions—these patients are more susceptible to the respiratory depressant effects of opioids.
- Hepatic impairment—since fentanyl is primarily metabolized by the liver, reduced hepatic function can lead to delayed clearance and prolonged or enhanced effects.
- Renal impairment—while fentanyl itself is primarily hepatically cleared, severe renal failure may affect the elimination of metabolites.
- Increased intracranial pressure or head injury—opioids can increase intracranial pressure and obscure the clinical assessment of neurological status.
- Myasthenia gravis—fentanyl may potentiate neuromuscular weakness.
- Bradyarrhythmias—fentanyl can cause or worsen bradycardia through vagal stimulation.
- Hypovolemia or hypotension—opioids can cause peripheral vasodilation and reduce sympathetic tone, potentially worsening hemodynamic instability.
- Elderly patients—reduced organ function and altered body composition necessitate dose reductions, typically 50% or more of standard adult doses.
- Opioid-dependent patients—these patients may require higher doses for adequate analgesia but are also at increased risk of withdrawal if antagonists are subsequently administered.
Rapid intravenous injection of fentanyl, particularly at higher doses, can cause chest wall rigidity (wooden chest syndrome), making ventilation extremely difficult or impossible. This effect is dose-dependent and more likely at doses exceeding 5 micrograms/kg administered rapidly. Treatment requires neuromuscular blocking agents and assisted ventilation. Fentanyl should always be administered slowly.
Pregnancy and Breastfeeding
Fentanyl crosses the placental barrier and can cause neonatal respiratory depression if administered to the mother during labor and delivery. When used during cesarean section, the timing and dose of fentanyl must be carefully coordinated with delivery of the infant. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), characterized by irritability, seizures, feeding difficulties, and tremors in the newborn.
Fentanyl is excreted in breast milk. Following a single anesthetic dose, breastfeeding can generally resume once the mother has recovered sufficiently from anesthesia. However, repeated or prolonged use requires careful assessment of the risk-benefit ratio, and monitoring of the nursing infant for signs of sedation, poor feeding, or respiratory depression is advised. The European Medicines Agency (EMA) recommends caution and consideration of the half-life and total exposure when making breastfeeding decisions.
How Does Leptanal Interact with Other Drugs?
Drug interactions with fentanyl are a critical safety concern because even small changes in fentanyl's pharmacokinetics or pharmacodynamics can have profound clinical consequences due to its high potency. The anesthesia team performs a careful medication reconciliation before any procedure involving fentanyl, but patients play an essential role by disclosing all medications, supplements, and substances they use.
Major Interactions
| Drug / Drug Class | Effect | Clinical Significance |
|---|---|---|
| MAO Inhibitors (e.g., phenelzine, tranylcypromine, selegiline) | Risk of serotonin syndrome, severe respiratory depression, hypotension, or hypertensive crisis | Contraindicated within 14 days of MAOI use. Potentially fatal interaction. |
| Benzodiazepines (e.g., midazolam, diazepam) | Profound sedation, respiratory depression, coma, death | FDA Black Box Warning. If concurrent use necessary, use lowest effective doses and shortest duration. |
| CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin, erythromycin, grapefruit juice) | Increased fentanyl plasma concentrations; prolonged and enhanced opioid effects | May require significant dose reduction. Monitor closely for respiratory depression. |
| Serotonergic Drugs (e.g., SSRIs, SNRIs, triptans, tramadol) | Risk of serotonin syndrome (agitation, hyperthermia, rigidity, clonus) | Monitor for serotonin syndrome signs. Discontinue fentanyl if syndrome suspected. |
| Other CNS Depressants (e.g., other opioids, general anesthetics, phenothiazines, barbiturates, alcohol) | Additive CNS and respiratory depression | Reduce fentanyl dose by 25–50%. Monitor respiratory and hemodynamic status. |
Minor Interactions
| Drug / Drug Class | Effect | Clinical Significance |
|---|---|---|
| CYP3A4 Inducers (e.g., rifampicin, carbamazepine, phenytoin) | Decreased fentanyl plasma levels; potential reduction in analgesic efficacy | Higher fentanyl doses may be needed. Monitor pain levels. |
| Anticholinergic Drugs (e.g., atropine, glycopyrrolate) | Increased risk of urinary retention and constipation | Often co-administered in anesthesia. Monitor bowel and bladder function postoperatively. |
| Muscle Relaxants (e.g., pancuronium, rocuronium) | Potential for enhanced neuromuscular blockade; bradycardia with pancuronium | Standard practice in anesthesia. Monitor neuromuscular function and heart rate. |
| Diuretics | Opioids can reduce efficacy of diuretics by inducing ADH release | Minor. Monitor fluid balance in prolonged use. |
Always inform your anesthesia team about all medications, including over-the-counter drugs, herbal supplements (particularly St. John's Wort, which is a CYP3A4 inducer), and any recreational substance use. This information is confidential and essential for your safety during the procedure.
What Is the Correct Dosage of Leptanal?
Fentanyl dosing in anesthesia is highly individualized and depends on multiple clinical factors. The anesthesiologist considers the patient's body weight, age, renal and hepatic function, hemodynamic status, the type and expected duration of the surgical procedure, the degree of surgical stimulation anticipated, and all concomitant medications. The following dosage guidelines represent general ranges used in clinical practice, based on recommendations from the European Medicines Agency (EMA), FDA prescribing information, and international anesthesia guidelines.
Adults
| Indication | Dose Range | Route | Notes |
|---|---|---|---|
| Low-dose supplement (minor surgery) | 1–2 mcg/kg | IV | Used with local or regional anesthesia. Minimal respiratory depression. |
| Moderate-dose (major surgery) | 2–20 mcg/kg | IV | Combined with inhaled agents. Supplemental doses of 25–100 mcg as needed. |
| High-dose anesthetic (cardiac surgery) | 50–100 mcg/kg | IV | Fentanyl as sole or primary anesthetic. Requires postoperative ventilation. |
| Continuous infusion (ICU sedation) | 0.5–3 mcg/kg/hr | IV infusion | Titrated to effect. May accumulate with prolonged use. |
| Epidural analgesia | 50–100 mcg | Epidural | Usually combined with local anesthetic. Monitor for delayed respiratory depression. |
Children
Pediatric dosing of fentanyl requires special consideration of the child's age, weight, and developmental physiology. Neonates and infants are particularly susceptible to fentanyl's respiratory depressant effects due to immature respiratory control mechanisms, reduced hepatic metabolism, and a higher proportion of body water affecting drug distribution.
Pediatric Dosing Guidelines
- Children 2–12 years: Induction: 1–3 mcg/kg IV. Maintenance: 1–2 mcg/kg supplemental doses as needed.
- Infants 3 months–2 years: 1–2 mcg/kg IV, with close respiratory monitoring. May have increased sensitivity.
- Neonates (<3 months): 0.5–2 mcg/kg IV. Extreme caution required. Prolonged elimination half-life (up to 18 hours in premature neonates). Must have continuous respiratory monitoring.
All pediatric doses must be carefully calculated based on actual body weight and administered by a pediatric anesthesiologist or a practitioner experienced in pediatric anesthesia.
Elderly
Elderly patients (aged 65 years and older) typically require 50% or greater dose reductions compared to younger adults. This is due to several age-related physiological changes: reduced hepatic blood flow and CYP3A4 activity leading to slower metabolism, decreased cardiac output affecting drug distribution, reduced lean body mass, increased body fat (extending the volume of distribution for lipophilic drugs), and a generally heightened sensitivity of the aging central nervous system to opioid effects.
The principle of "start low and go slow" is paramount in elderly patients. Initial doses should be conservative, with careful titration based on clinical response. Recovery from fentanyl may be prolonged in this population, and extended postoperative monitoring for respiratory depression is recommended.
Missed Dose
The concept of a "missed dose" does not apply to Leptanal in the traditional sense, as it is administered by healthcare professionals in clinical settings rather than taken by patients on a scheduled basis. Dosing is continuously adjusted in real time based on the patient's physiological responses during the procedure. If additional analgesia is required, supplemental doses are administered as clinically indicated.
Overdose
Fentanyl overdose manifests primarily as severe respiratory depression (respiratory rate below 8 breaths per minute or apnea), profound sedation or loss of consciousness, miosis (pinpoint pupils), skeletal muscle rigidity (particularly of the chest wall), bradycardia, and hypotension. If untreated, respiratory depression leads to hypoxia, cardiac arrest, and death.
The primary treatment for fentanyl overdose is the opioid antagonist naloxone (Narcan). Initial dose is 0.4–2 mg IV, which may be repeated every 2–3 minutes as needed. Because fentanyl's duration of action may exceed that of naloxone, continuous monitoring and repeat dosing or a naloxone infusion may be necessary. Supportive measures include assisted ventilation (bag-mask ventilation or endotracheal intubation), hemodynamic support with IV fluids and vasopressors, and management of chest wall rigidity with neuromuscular blocking agents if ventilation is impaired.
What Are the Side Effects of Leptanal?
Like all opioid analgesics, Leptanal produces a range of pharmacological effects beyond analgesia. Many of these are predictable consequences of mu-opioid receptor activation and are dose-dependent. The side effect profile in a given patient depends on the dose administered, the speed of injection, the patient's age and overall health, concurrent medications, and the clinical context (e.g., intraoperative use with mechanical ventilation versus postoperative use with spontaneous breathing).
The following classification uses the standard frequency categories recommended by the Council for International Organizations of Medical Sciences (CIOMS) and adopted by the European Medicines Agency (EMA): Very Common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (<1/1,000).
Very Common (≥1/10)
- Nausea and vomiting (postoperative)
- Muscle rigidity (including chest wall rigidity at higher doses)
- Sedation and drowsiness
- Respiratory depression (dose-dependent)
- Miosis (pupil constriction)
Common (1/100 to 1/10)
- Bradycardia (slow heart rate)
- Hypotension (low blood pressure)
- Dizziness and vertigo
- Constipation and reduced gastrointestinal motility
- Pruritus (itching)
- Urinary retention
- Postoperative confusion or agitation
- Laryngospasm
Uncommon (1/1,000 to 1/100)
- Hypertension (paradoxical, especially with pancuronium)
- Tachycardia
- Euphoria or dysphoria
- Visual disturbances
- Bronchospasm
- Myoclonus (involuntary muscle jerks)
- Diaphoresis (excessive sweating)
Rare (<1/1,000)
- Anaphylaxis and severe allergic reactions
- Seizures
- Asystole (cardiac arrest)
- Serotonin syndrome (when combined with serotonergic drugs)
- Adrenal insufficiency (with prolonged use)
- Severe respiratory arrest
In the postoperative period, notify your nurse or doctor immediately if you experience unusual drowsiness, difficulty breathing, severe itching, confusion, inability to urinate, or any other unusual symptoms. These can indicate that additional monitoring or treatment adjustments are needed.
How Should Leptanal Be Stored?
Leptanal is a Schedule II controlled substance in most jurisdictions, which imposes strict regulatory requirements on its storage, handling, and accounting. In hospital settings, fentanyl is typically stored in a locked controlled substances cabinet or automated dispensing system (e.g., Pyxis or Omnicell) with electronic tracking of every ampoule removed. Access is restricted to authorized healthcare personnel.
The physical storage conditions for Leptanal solution for injection are straightforward: store at temperatures below 25°C (77°F), protect from light, and keep the ampoules in the original carton until ready for use. The solution should be clear and colorless; do not use if the solution appears discolored or contains particulate matter. Once an ampoule is opened, any unused portion must be discarded immediately in accordance with controlled substance disposal protocols—fentanyl must never be saved for later use from an opened ampoule.
The shelf life of unopened Leptanal ampoules is typically 36 months (3 years) from the date of manufacture, though this should be confirmed by checking the expiration date on each individual ampoule and carton. Do not use after the expiry date printed on the packaging.
What Does Leptanal Contain?
Leptanal is formulated as a clear, colorless, sterile aqueous solution for parenteral administration. The formulation is intentionally simple to minimize the risk of incompatibilities and adverse reactions to excipients.
Active Ingredient
- Fentanyl citrate equivalent to 50 micrograms of fentanyl base per milliliter. Fentanyl citrate is the salt form used in injectable preparations because of its water solubility (approximately 25 mg/mL in water) and stability in aqueous solution.
Inactive Ingredients (Excipients)
- Sodium chloride—used to make the solution isotonic with blood, preventing discomfort and hemolysis at the injection site.
- Water for injections—the vehicle and solvent for the formulation, meeting pharmacopeial standards for sterility and pyrogen-free quality.
- Hydrochloric acid and/or sodium hydroxide—used as needed to adjust the pH of the solution to approximately 4.0–7.5, ensuring stability and tolerability.
The solution is preservative-free in most formulations, which means single-use ampoules must be used immediately after opening. The typical packaging is glass ampoules containing 2 mL (100 micrograms total) or 10 mL (500 micrograms total) of solution. Consult your regional product information for specific ampoule sizes available in your country.
Frequently Asked Questions About Leptanal
Leptanal (fentanyl) is used primarily in hospital settings as an analgesic component of general anesthesia during surgical procedures. It is also used for perioperative pain management, as a supplement to regional or local anesthesia, and for sedation and analgesia in intensive care units. It is administered only by trained healthcare professionals in monitored clinical environments equipped with resuscitation capabilities.
Leptanal (fentanyl) is approximately 80 to 100 times more potent than morphine on a weight-for-weight basis. This means that 100 micrograms (0.1 mg) of fentanyl produces approximately the same analgesic effect as 8–10 mg of morphine. This extreme potency is why fentanyl is dosed in micrograms rather than milligrams and why it must be handled with great precision by trained practitioners.
The most serious side effect is respiratory depression, which can be life-threatening if not immediately recognized and treated. Other serious adverse effects include severe bradycardia, profound hypotension, chest wall rigidity (which can make ventilation impossible), anaphylaxis, and cardiac arrest. These risks are managed through continuous monitoring during and after administration, with naloxone and resuscitation equipment immediately available.
Fentanyl is a Schedule II controlled substance with a recognized potential for abuse and physical dependence. However, when used for its intended clinical purposes—such as during surgical anesthesia—under medical supervision, the risk of developing addiction from acute hospital use is very low. Prolonged use in intensive care settings may lead to physical dependence, which is managed through gradual dose tapering when discontinuing the medication. It is important to distinguish between physical dependence (a physiological adaptation) and addiction (a behavioral disorder).
Leptanal is an injectable formulation designed for acute use in hospitals during anesthesia and procedural sedation. Fentanyl patches (transdermal delivery systems such as Durogesic or Duragesic) are a completely different formulation designed for chronic pain management in opioid-tolerant patients. The injectable form has a very rapid onset (1–2 minutes IV) and relatively short duration (30–60 minutes per dose), whereas patches provide slow, steady release of fentanyl over 72 hours. Patches must never be used in opioid-naive patients due to the risk of fatal respiratory depression.
Inform your anesthetist about all medications you are taking (including over-the-counter drugs, herbal supplements, and recreational substances), any previous adverse reactions to opioids or other anesthetics, history of substance use disorders, liver or kidney disease, respiratory conditions (COPD, asthma, sleep apnea), head injuries or brain tumors, myasthenia gravis, cardiac arrhythmias, and whether you are pregnant, planning to become pregnant, or breastfeeding. This information is essential for determining the safest anesthetic plan for you.
References
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023. Available at: who.int/publications
- European Medicines Agency (EMA). Fentanyl – Summary of Product Characteristics. Amsterdam: EMA; 2024. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). SUBLIMAZE (fentanyl citrate) Injection – Prescribing Information. Silver Spring, MD: FDA; 2023.
- British National Formulary (BNF). Fentanyl. London: NICE; 2024. Available at: bnf.nice.org.uk
- Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999;90(2):576–599. doi:10.1097/00000542-199902000-00034
- Grape S, Schug SA, Lauer S, Schug BS. Formulations of fentanyl for the management of pain. Drugs. 2010;70(1):57–72. doi:10.2165/11530800-000000000-00000
- Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: An update. Clin Pharmacokinet. 1996;31(4):275–292. doi:10.2165/00003088-199631040-00004
- Nelson LS, Olsen D. Opioid overdose. N Engl J Med. 2022;386:2132–2142. doi:10.1056/NEJMra2202308
- Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–S153.
- Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983;8(5):422–446. doi:10.2165/00003088-198308050-00004
Editorial Team
Medical Review
This article was reviewed by the iMedic Medical Review Board, comprising board-certified specialists in anesthesiology, pharmacology, and pain medicine. All medical claims are supported by Level 1A evidence from systematic reviews and clinical guidelines.
Editorial Standards
iMedic follows international guidelines from WHO, EMA, FDA, and BNF. Our content is free from commercial influence, with no pharmaceutical sponsorship. We use the GRADE evidence framework and update articles when new evidence emerges.